Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gynomax XL vs Gynomax in vaginal infections
DRKS00016648Phase 3Completed
- Sponsor
- Exeltis Healthcare S.L. (Spain) Moscow representative office of Exeltis Healthcare S.L. (Spain) 16 Malaya Pirogovskaya st., office 61 119435 Moscow Russia
- Start
- Feb 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Gynomax in trichomoniasis (trich), vulvovaginal candidiasis (VVC), bacterial vaginosis (BV) and 1 more (2 arms), sponsored by Exeltis Healthcare S.L. (Spain) Moscow representative office of Exeltis Healthcare S.L. (Spain) 16 Malaya Pirogovskaya st., office 61 119435 Moscow Russia. Started Feb 2019; status: completed.
02
Drugs
Gynomax
03
Conditions
trichomoniasis (trich)vulvovaginal candidiasis (VVC)bacterial vaginosis (BV)vaginitis
Beyond the preview
Go deeper on DRKS00016648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00016648.